Actinium Pharmaceuticals ATNM shares are trading higher after the company announced it completed enrollment in the pivotal Phase 3 SIERRA trial of iomab-B.
Actinium Pharmaceuticals' stock has been rising Wednesday, up 19.18% to a price of $6.87. The stock's current volume for the day is 746.12 thousand, which is approximately 435.17% of its previous 30-day average volume of 171.45 thousand.
The stock's 50-day moving average was $6.59 at the time this article was published. Over the past fifty-two weeks, the price has risen as high as $13.18 and fallen to a low of $5.7.
If you're looking for timely and concise explanations of why a stock is moving, check out Benzinga Pro. Subscribers get ‘Why Is It Moving' alerts as soon as our research team identifies the cause of the price action in a stock. Click here to learn more.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
